Used in cancer therapy to inhibit tumor angiogenesis by blocking the Delta-like ligand 4 (DLL4) pathway, which plays a critical role in regulating blood vessel formation. By targeting DLL4, this antibody disrupts the Notch signaling pathway, leading to the formation of non-functional vasculature within tumors, thereby restricting tumor growth and metastasis. It is particularly investigated for use in solid tumors such as colorectal, lung, and breast cancers. Due to its mechanism, it may overcome resistance to VEGF inhibitors when used alone or in combination with other anti-angiogenic agents. Its application is primarily in preclinical research and therapeutic development under patented Smart Targeting technology for improved tumor specificity and efficacy.